<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potential reasons for lack of response to epinephrine in anaphylaxis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potential reasons for lack of response to epinephrine in anaphylaxis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Potential reasons for lack of response to epinephrine in anaphylaxis</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Relevant studies</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Patient/caregiver/clinician</td> </tr> <tr> <td class="indent1">Rapid anaphylaxis progression</td> <td>Case reports, autopsy reports</td> <td>In 10% of anaphylaxis episodes, epinephrine does not work, even if given promptly</td> </tr> <tr> <td class="indent1">Epinephrine given too late</td> <td>Case reports, autopsy reports</td> <td>Cause-and-effect hard to prove</td> </tr> <tr class="divider_bottom"> <td class="indent1">Individuals do not know how to use epinephrine autoinjectors</td> <td>Cross-sectional surveys, demonstrations</td> <td>Frequently reported</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Epinephrine-related</td> </tr> <tr> <td class="indent1">Dose too low</td> <td>Few dose response studies</td> <td>Optimal dose unknown; based on tradition, 0.3 mg is used for adults in many countries, 0.5 mg in some countries</td> </tr> <tr> <td class="indent1">Lack of availability of fixed doses 0.05, 0.1, 0.2, 0.25 mg in autoinjectors</td> <td> </td> <td>Impossible to give an appropriate dose to infants and to some young children</td> </tr> <tr> <td class="indent1" rowspan="3">Route/site not optimal</td> <td>Intramuscular versus subcutaneous*</td> <td>Intramuscular, thigh preferred to subcutaneous, arm</td> </tr> <tr> <td>Ampule and syringe*</td> <td>Nonmedical personnel lack speed and accuracy</td> </tr> <tr> <td>Pressurized metered-dose inhaler (MDI)<sup>¶</sup></td> <td>For systemic effects, adults need 20 to 30 puffs (children 10 to 20; has been phased out in most countries)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Past expiration date</td> <td>Bioavailability measured in animal models; content measured in vitro<sup>Δ</sup></td> <td>Epinephrine content inversely related to number of months past expiration date</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Other</td> </tr> <tr> <td class="indent1">Individual not supine</td> <td>Autopsy reports</td> <td>If the individual is standing, venous return is decreased, the ventricles are empty, and death may occur despite timely epinephrine-induced reversal of vasodilation and shock</td> </tr> <tr> <td class="indent1">Individual taking medications (beta-blocker or alpha-blocker, angiotensin-converting enzyme inhibitor) that prevent optimal epinephrine effect</td> <td>Case reports</td> <td>There is more information about lack of effect in asthma than in anaphylaxis</td> </tr> <tr> <td class="indent1">Adverse effects of sodium metabisulfite (antioxidant in epinephrine)</td> <td>Case reports</td> <td>Additional studies needed, because sulfite-sensitive asthmatics tolerate epinephrine</td> </tr> </tbody></table></div><div class="graphic_footnotes">* In obese individuals, intramuscular injections of epinephrine may inadvertently end up being subcutaneous injections unless a needle at least 2.5 cm (1 in) is used to penetrate the aft pad over the vastus lateralis muscle.<br/>¶ It is difficult to inhale the large number of epinephrine puffs required because of vasoconstriction of the oropharyngeal mucosa, causing tingling and burning sensations.<br/>Δ Compendial limits for epinephrine content of formulations are 90 to 115% of labeled strength (United States Pharmacopeia), but in some countries, the stated content of epinephrine in autoinjectors may range from 0.23 mg to 0.37 mg. Epinephrine should be stored at room temperature (15 to 30°C) to prevent oxidation and inactivation. In an EpiPen autoinjector, it is supplied in light-resistant packaging, and each 0.3 mL dose contains 0.3 mg epinephrine, 1.8 mg sodium chloride, 0.5 mg sodium metabisulfite, and hydrochloric acid to adjust the pH from 2.2 to 5.0. An EpiPen Jr contains epinephrine 0.15 mg and the same nonmedicinal ingredients in the same amounts as in the EpiPen.</div><div class="graphic_reference">Reproduced with permission from: Simons FER. First-aid treatment of anaphylaxis to food: Focus on epinephrine. J Allergy Clin Immunol 2004; 113:837. Copyright ©2004 Elsevier.</div><div id="graphicVersion">Graphic 61580 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
